The research effort will seek to determine optimal spatial separation between vaccination sites on the body to avoid immune interference between multiple vaccines.
The final testing will involve delivery of Lassa and Hantaan virus vaccines simultaneously at spatially distinct sites.
Inovio president and CEO Joseph Kim said this device would provide a means to painlessly deliver multiple vaccines simultaneously, bringing improved protection against infectious diseases to both military and civilian populations.
"This collaboration builds on Inovio’s strong relationship with the US DOD, in which Inovio is bringing medical innovation to multiple bio-defense projects," Kim said.